Company intelligence / Profile preview

VedaBio

San Diego, California, United Statesvedabio.com ↗

Ownership: Private
Employees: ~25
Development stage: Preclinical

Overview

VedaBio has developed the CRISPR Cascade™ platform for ultra-fast, highly accurate molecular detection without target amplification. The technology enables near-instant results (<1 minute), high multiplexing capability, and room temperature operation. The company has raised over $40 million in funding and aims to launch its first flagship product soon. No clinical trial results have been published yet.

Therapeutic areas: Infectious Diseases
Modalities: Molecular diagnostics (CRISPR-based detection platform; not a therapeutic modality company)
Industry: Molecular Diagnostics

Partnerships

Not publicly announced as of May 2025

Beyond the preview

Go deeper on VedaBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VedaBio.

Explore the full profile